HPS Pharmacies wish to give notice that Merck Sharp & Dohme (Australia) are discontinuing Keytruda® 50mg powder for injection as follows:
Keytruda® Powder for Injection
Pembrolizumab (rch) 50mg
Keytruda® 50mg powder for injection will be discontinued in Australia this year. This product is still listed on the Pharmaceutical Benefits Scheme (PBS). However, supplies are currently limited.
Keytruda® 100mg/4mL concentrated injection vial will be the only presentation of Keytruda® available following discontinuation of the 50mg powder for injection.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Merck Sharp & Dohme (Australia) on (02) 8988 8000 or your pharmacist at HPS Pharmacies.